Unity Biotechnology, Inc. UBX
Set alert
At close · Jul 2
- YTD
- -79.51%
- 1 year
- -84.95%
- Open
- 0.2001
- Prev close
- 0.2001
- Mkt cap
- 16.85M
- Vol
- 0
- Avg vol
- 67.22K
- EPS
- -1.28
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.2001
- High
- 0.2001
- Forward P/E
- -0.57
- Beta
- 0.83
- Short ratio
- 3.52
- Inst. own
- 20.55%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 6, 2024
- 50-d avg
- 1.24
- 200-d avg
- 1.43
- 1y target
- 7.00
Key statistics
- Market cap
- 16.85M
- Enterprise value
- 11.57M
- Trailing P/E
- 0.00
- Forward P/E
- -0.57
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.19
- EPS (TTM)
- -1.28
- Beta
- 0.83
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -10.16M
- Total cash
- 29.04M
- Total debt
- 24.43M
- Return on equity
- -86.95%
- Shares outstanding
- 16.85M
- Short % of float
- 1.55%
- 50-day average
- 1.24
- 200-day average
- 1.43
Analyst view
Consensus: none
- Target (low)
- 6.00
- Target (mean)
- 7.00
- Target (high)
- 8.00
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 6, 2024
Expected Aug 6, 2024. Consensus EPS estimate -0.43443.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2024 | Sep 1, 2024 | -0.40 | -0.38 | +0.02 | +5.00% |
| Aug 6, 2024 | Jun 1, 2024 | -0.44 | -0.31 | +0.13 | +29.55% |
| Aug 6, 2024 | Jun 1, 2024 | -0.44 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | -0.57 | -0.34 | +0.23 | +40.35% |
| May 14, 2024 | Mar 1, 2024 | -0.57 | — | — | — |
| Apr 15, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 8, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 16, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Nov 16, 2023 | Wedbush | up | Neutral | Outperform |
| Nov 14, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 9, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
About Unity Biotechnology, Inc.
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- unitybiotechnology.com
News
- UBX Tanzania Deepens Partnership with ACI Worldwide to Power the Next Phase of the Nation's Digital Economy
- 12 Health Care Stocks Moving In Tuesday's Intraday Session
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- US Stocks Likely To Open Higher: S&P 500 Sees 'Average Gain Of 6.1%' In 2nd Half, Expert Says
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- 12 Health Care Stocks Moving In Monday's Intraday Session
- 12 Health Care Stocks Moving In Tuesday's Intraday Session
- PTC Therapeutics To Rally Around 61%? Here Are 10 Top Analyst Forecasts For Tuesday
- UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting
- UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates
Your note
Sign in to keep a note on UBX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DANANBERG JAMIE | Officer | Sale | Mar 30, 2023 | 62,817 |
| GHOSH ANIRVAN | Chief Executive Officer | Sale | Nov 3, 2024 | 75,893 |
| NGUYEN ALEXANDER HIEU | Officer | Sale | Nov 3, 2024 | 24,723 |
| SULLIVAN LYNNE MARIE | Officer | Sale | Nov 3, 2024 | 55,925 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Arch Venture Management, Llc | 5.96% | 1,004,817 | 1.00M | Sep 29, 2024 |
| Alyeska Investment Group, L.p. | 5.46% | 920,013 | 919.74K | Sep 29, 2024 |
| Vanguard Group Inc | 3.51% | 590,770 | 590.59K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.97% | 163,242 | 163.19K | Sep 29, 2024 |
| Mayo Clinic | 0.74% | 124,081 | 124.04K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.56% | 93,670 | 93.64K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.35% | 395,985 | 395.87K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.16% | 194,785 | 194.73K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.52% | 88,367 | 88.34K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.16% | 27,636 | 27.63K | Oct 30, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.15% | 25,000 | 24.99K | Sep 29, 2024 |
| Fidelity Series Total Market Index Fund | 0.12% | 20,964 | 20.96K | Oct 30, 2024 |